5 completed, 3 recruiting, 1 active not recruiting. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 5, Recruiting 3, Active not recruiting 1 |
Follow Farxiga: new trials by email Literature Review of Farxiga trials Research Report on Farxiga
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGLT2i, Pioglitazone, and Ketone Production in T1D Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo - Type1diabetes | Phase 3 | Recruiting | The University of Texas Health Science Center at San Antonio | 24 | 2026-07-01 | 2026-07-20 |
| CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL Dapagliflozin, Placebo - Breast Cancer, Heart Failure | Phase 3 | Recruiting | 4th Military Clinical Hospital with Polyclinic, Poland | 188 | 2024-04-15 | 2024-12-04 |
| SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF Dapagliflozin 10mg Tab, Placebo Tab - Chronic Coronary Syndrome, Atrial Fibrillation | Phase 3 | Recruiting | Region Örebro County | 800 | 2024-04-04 | 2025-04-08 |
| Dapagliflozin in Patients With Critical Illness Dapagliflozin 10mg Tab, Standard of Care - Critical Illness, Sepsis | Phase 3 | Completed | Hospital Israelita Albert Einstein | 507 | 2022-11-01 | 2023-10-31 |
| DAPAgliflozin for Renal Protection in Heart Transplant Recipients Dapagliflozin 10 mg, Placebo - Heart Transplant Failure, Kidney Failure | Phase 3 | Active not recruiting | Oslo University Hospital | 430 | 2022-06-08 | 2026-07-01 |
| Dapagliflozin in Respiratory Failure in Patients With COVID-19 Dapagliflozin 10 milligram (mg), Placebo - COVID-19 | Phase 3 | Completed | Saint Luke's Health System | 1250 | 2020-04-22 | 2022-06-10 |
| Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin Dapagliflozin, Placebo - Type II; Diabetes | Phase 3 | Completed | The University of Texas Health Science Center at San Antonio | 30 | 2017-09-06 | 2019-12-18 |
| SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 Dapagliflozin, Placebo - Type II Diabetes Mellitus | Phase 3 | Completed | The University of Texas Health Science Center at San Antonio | 30 | 2015-10-23 | 2020-09-17 |
| Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Dapagliflozin, Insulin, Liraglutide - Type 1 Diabetes Mellitus | Phase 3 | Completed | University at Buffalo | 26 | 2015-08-01 | 2024-01-24 |
Diabetes Mellitus, Type 2 (2) · Acute Kidney Injury (1) · Atrial Fibrillation (1) · Breast Neoplasms (1) · COVID-19 (1) · Critical Illness (1) · Diabetes Mellitus, Type 1 (1) · Heart Failure (1) · Renal Insufficiency (1) · Sepsis (1)
The University of Texas Health Science Center at San Antonio (3) · 4th Military Clinical Hospital with Polyclinic, Poland (1) · Hospital Israelita Albert Einstein (1) · Oslo University Hospital (1) · Region Örebro County (1) · Saint Luke's Health System (1) · University at Buffalo (1)
United States (5) · Brazil (2) · Sweden (2) · Argentina (1) · Canada (1) · Czechia (1) · Denmark (1) · India (1) · Mexico (1) · Netherlands (1) · Norway (1) · Poland (1) · United Kingdom (1)
Eugenio Cersosimo, MD,PhD (1) · Kevin Damman, MD, PhD (1) · Mariusz Szymanski, MD, PhD (1) · Mikhail Kosiborod, MD (1) · Muhammad Abdul-Ghani, MD (1) · Nitesh D Kuhadiya, MD, MPH (1) · Olivier Manintveld, MD, PhD (1) · Oscar Braun, MD, PhD (1) · Otavio Berwanger, PhD (1) · Ralph A. DeFronzo, MD (1) · Ralph DeFronzo, MD (1) · Waldemar Banasiak, PhD, MD (1)
PMID 27490915, PMID 31915153, PMID 34302745, PMID 35699910, PMID 38133155, PMID 38770818, PMID 38873723, PMID 39928546, PMID 40739638, PMID 40840822, PMID 41421016
2023 (1), R01DK024092 (1), R01DK107680 (1)